I-Mab (NASDAQ:NBP) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of I-Mab (NASDAQ:NBP) from a hold rating to a sell rating in a research note issued to investors on Sunday morning.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of I-Mab in a report on Thursday, August 20th. Weiss Ratings raised I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, I-Mab currently has a consensus rating of “Hold” and an average target price of $9.00.

I-Mab Stock Performance

Shares of I-Mab stock opened at $1.84 on Friday. The company has a 50 day moving average of $1.82 and a 200-day moving average of $2.23. I-Mab has a 1-year low of $1.46 and a 1-year high of $6.79. The company has a market cap of $212.80 million, a PE ratio of -5.11 and a beta of 1.47.

I-Mab (NASDAQ:NBP) last posted its quarterly earnings results on Thursday, August 20th. The company reported ($0.16) earnings per share (EPS) for the quarter. Research analysts forecast that I-Mab will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On I-Mab

An institutional investor recently bought a new position in I-Mab stock. Brooklyn Investment Group bought a new stake in I-Mab (NASDAQ:NBP) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,715 shares of the company’s stock, valued at approximately $51,000. Institutional investors own 38.38% of the company’s stock.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.